RESEARCH TRIANGLE PARK — United Therapeutics has applied for a priority review voucher and submitted a new drug application to the United States Food and Drug Administration, the company announced this week. The drug, Tyvaso DPI™, is a novel dry powder inhalation formulation of treprostinil, and, if approved, will be used to treat pulmonary arterial hypertension (PAH).
The company estimates there are about 30,000 treatable patients in the United States, according to a statement.
{iframe}https://www.wraltechwire.com/2021/04/20/united-therapeutics-submits-new-drug-application-to-fda-to-treat-pulmonary-arterial-hypertension/{/iframe}